Advertisement
"Because the antipsychotic market has not been stringent on formularycontrols, the availability of generic risperidone will allow payers to placecontrols on branded antipsychotics and also place these agents on higher copaytiers," said Michael Malecki, Ph.D., analyst at Decision Resources. "Manyschizophrenia patients will be required to take the generic form of Risperdalbefore they are reimbursed for treatment with other drugs. However, we don'texpect patients who are currently stable on an antipsychotic to switch togeneric risperidone."
Advertisement
The new report entitled Treatment Algorithms in Schizophrenia also findsthat other atypicals capture patient share via their efficacy versus specificsymptoms. Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify is favored by33 percent of surveyed psychiatrists for cases of schizophrenia with negativesymptoms and 28 percent choose it for schizophrenia with cognitivedysfunction. Cases of schizophrenia with agitation call for AstraZeneca'sSeroquel first-line, according to 37 percent of surveyed psychiatrists whereascases of schizophrenia with anxiety call for Seroquel first-line, according to46 percent of surveyed psychiatrists.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the mostextensive claims-based longitudinal patient-level data from PharMetrics(R) toprovide exceptional insight into physicians' prescribing trends and thefactors that drive therapy product choice, from diagnosis through multiplecourses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment Algorithm InsightSeries provides the following:
-- Summary of United States medical practice based on interviews withleading experts in the field
-- Qualitative diagnosis/referral/treatment algorithm for the UnitedStates
-- Drug usage by lines of therapy (1st, 2nd, 3rd line)
-- Discussion of key freeform combinations by lines of therapy
-- Product share (class and specific compound level) within each line oftherapy (1st, 2nd, 3rd line)
-- Progression of therapy from key 1st line products
-- Pathway to key therapies from previous therapies
-- Qualitative analysis of two-year forecast incorporating upcominglaunches, changes in reimbursement, etc
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services and consulting designed to helpclients shape strategy, allocate resources and master their chosen markets.Decision Resources is a Decision Resources, Inc. company.
All company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 [email protected]
SOURCE Decision Resources
